Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Presentation by Melissa Penny, Swiss TPH - The global health perspective (innovation for neglected diseases)

204 views

Published on

Someone who knows how to cope with innovation and no financial return on investment is Melissa Penny, professor at the Swiss TPH. She shared her insights on finding therapies for neglected diseases, which are often non-profitable. Her approach is to ensure evidence of a new therapeutic or cure for those diseases is “profitable” from a global health perspective. By utilising modelling and simulating as well as data analytics the effectiveness of an intervention throughout the whole value chain can be demonstrated to support payers to make the best decision possible.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

Presentation by Melissa Penny, Swiss TPH - The global health perspective (innovation for neglected diseases)

  1. 1. Epidemiology and Public Health Infectious Disease Modelling The global health perspective (innovation for neglected diseases) Prof Melissa Penny, Swiss Tropical and Public Health Institute melissa.penny@unibas.ch 7th May 2019
  2. 2. New therapeutics for global health Bench to field Discovery, Development, Implementation Innovation value chain in global health
  3. 3. New therapeutics for global health Preclinical Early clinical Clinical Implementation Translation Translation Translation Public health benefit Save lives Save costs
  4. 4. New therapeutics for global health Modelling and simulation – supporting product development and evaluation of novel therapeutics across the innovation value chain Preclinical Early clinical Clinical Implementation Translation Translation Translation Modelling and simulation throughout development to reach implementation Modelling and simulation to inform innovation/development
  5. 5. New therapeutics for global health Models DATA Policy & investment decisions or evidence for payer perspective
  6. 6. Donor driven R&D to global policy and implementation Multiple actors for innovation Product development partnerships$$$ Innovative vector control consortium $$$ R&D funders Payers: National Malaria programs, Global Fund, PMI, GAVI, & & Recommendations 1) WHO Pre-qualification 2) WHO Policy recommendations 3) National Health Ministry Academia Industry
  7. 7. Lessons learnt Data! Innovation and knowledge gaps Equitable effectiveness Actors Incentives Partnerships
  8. 8. Decision making in healthModels Iterative Intervention Target product profiles/use cases of new malaria tools Evidence generation for quantitative intervention Target Product Profiles Identify innovation gaps for greater impact Identify limitations Iterative DATA Lessons learnt – we need to identify innovation and knowledge gaps Machine LearningPartnerships and decision makers
  9. 9. Funding: Thank you and acknowledgements Melissa Penny Guojing Yang Monic Golumbeanu Flavia Camponovo Tom Smith Members of Swiss TPH Infectious Disease modelling unit Collaborators at Swiss TPH Collaborators from MVI, IVCC, MMV, and Bill & Melinda Gates Foundation

×